Background/Purpose To evaluate whether on-treatment HBV-DNA level could predict the
treatment response to entecavir in hepatitis B e antigen (HBe)-positive chronic hepatitis B …

Background Hepatitis B e antigen (HBeAg) status is associated with clinical outcomes, and
seroconversion of HBeAg is one of the treatment goals. In this study, we determined the …

Background/Purpose Several anti-viral drugs are approved for the treatment of hepatitis B
virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg) …

Objective To investigate the dynamic changes of serum HBsAg and hepatitis B virus (HBV)
DNA in chronic hepatitis B patients (CHB) with entecavir (ETV) monotherapy for 5 years …

Background and aims To evaluate the antiviral response of hepatitis B e antigen (HBeAg)-
positive chronic hepatitis B (CHB) patients who had baseline high viral load (HVL), defined …

Background & aims Virological breakthrough (VBT) could be a manifestation of chronic
hepatitis B (CHB) in patients treated with long-term nucleot (s) ide analogues. We aimed to …

Objective To evaluate the efficacy of entecavir treatment up to 96 weeks for patients with
chronic hepatitis B (CHB). Methods The study recruited 62 CHB patients who were admitted …

Quantitative hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) assays
are emerging as effective tools of on‐treatment predictors of response to antiviral agents, in …

Background Whether the decline of hepatitis B virus (HBV) RNA was associated with
antiviral efficacy in chronic hepatitis B (CHB) patients receiving long-term nucleos (t) ide …

Objective To investigate the influencing factors for persistent low-level viremia (LLV) in
chronic hepatitis B (CHB) patients receiving long-term entecavir antiviral therapy. Methods …